Latest news with #Cosentyx
Yahoo
20-07-2025
- Business
- Yahoo
Novartis Sacrifices A Breakout As One Of Its Bread-And-Butter Drugs Misses
Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers. Sign in to access your portfolio
Yahoo
10-07-2025
- Health
- Yahoo
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS) Following this important milestone, Cosentyx has been listed in Québec MONTRÉAL, July 10, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx (secukinumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS), a chronic, painful and often debilitating inflammatory skin condition.1 Following the completion of these negotiations, Cosentyx has been listed in Québec, making it the first province to provide public reimbursement for Cosentyx in HS. Novartis remains committed to ongoing collaboration with provincial public drug programs across Canada to enable timely access and reimbursement for eligible patients nationwide. "Too often, people living with HS feel like their condition is invisible within the healthcare system," said Latoya Palmer, Founder of Hidradenitis and Me Support Group. "As someone living with HS, it gives me hope to see this step forward. It feels validating and shows people like me that there is a path toward better support for those who need it most." "For people living with moderate to severe HS, the condition can have a profound impact on daily life - not only due to physical symptoms, but also the emotional toll it can take," said Dr. Susan Poelman, Canadian and U.S. Board-Certified Dermatologist. "The conclusion of pCPA negotiations for Cosentyx is a promising step that could help expand possibilities for patients who have historically had limited treatment options." "Concluding pCPA negotiations for Cosentyx in HS is an important step toward improving access to a therapy grounded in strong science and real patient need," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "At Novartis, we are committed to continuing to work with stakeholders across the healthcare system to help ensure eligible patients with HS have timely public access to innovative treatment options." About Cosentyx® (secukinumab) Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in many inflammatory diseases.2,3 Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), Axial spondyloarthritis (axSpA) and juvenile idiopathic arthritis (JIA).4,5,6,7,8,9 These data strengthen the position of Cosentyx as a treatment across moderate to severe PsO (adult and pediatric), PsA, HS, axial spondyloarthritis (axSpA), and juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis and juvenile PsA. More than 1 million patients have been treated with Cosentyx worldwide since its launch in 2015. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit FA-11466794E_________________________________1 Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Accessed on June 6, 2025. Available at: Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012; 167: 717-724. Accessed on June 6, 2025. Available at: Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 2019; 5: e001005.5 Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-1514.6 Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol 2020; 2: 18-25.7 Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.8 Data on file. CAIN457F2312 (FUTURE 2): 5 year-interim report. Novartis Pharmaceuticals Corp; May 2019.9 McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1137-1146. SOURCE Novartis Pharmaceuticals Canada Inc. View original content to download multimedia:
Cision Canada
10-07-2025
- Health
- Cision Canada
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) Français
Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS) Following this important milestone, Cosentyx has been listed in Québec MONTRÉAL, July 10, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx (secukinumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS), a chronic, painful and often debilitating inflammatory skin condition. 1 Following the completion of these negotiations, Cosentyx has been listed in Québec, making it the first province to provide public reimbursement for Cosentyx in HS. Novartis remains committed to ongoing collaboration with provincial public drug programs across Canada to enable timely access and reimbursement for eligible patients nationwide. "Too often, people living with HS feel like their condition is invisible within the healthcare system," said Latoya Palmer, Founder of Hidradenitis and Me Support Group. "As someone living with HS, it gives me hope to see this step forward. It feels validating and shows people like me that there is a path toward better support for those who need it most." "For people living with moderate to severe HS, the condition can have a profound impact on daily life - not only due to physical symptoms, but also the emotional toll it can take," said Dr. Susan Poelman, Canadian and U.S. Board-Certified Dermatologist. "The conclusion of pCPA negotiations for Cosentyx is a promising step that could help expand possibilities for patients who have historically had limited treatment options." "Concluding pCPA negotiations for Cosentyx in HS is an important step toward improving access to a therapy grounded in strong science and real patient need," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "At Novartis, we are committed to continuing to work with stakeholders across the healthcare system to help ensure eligible patients with HS have timely public access to innovative treatment options." About Cosentyx ® (secukinumab) Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in many inflammatory diseases. 2,3 Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), Axial spondyloarthritis (axSpA) and juvenile idiopathic arthritis (JIA). 4,5,6,7,8,9 These data strengthen the position of Cosentyx as a treatment across moderate to severe PsO (adult and pediatric), PsA, HS, axial spondyloarthritis (axSpA), and juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis and juvenile PsA. More than 1 million patients have been treated with Cosentyx worldwide since its launch in 2015. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit FA-11466794E SOURCE Novartis Pharmaceuticals Canada Inc.
Yahoo
04-07-2025
- Health
- Yahoo
Novartis' Cosentyx shows no benefit in Phase III GCA trial
Novartis' Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), Cosentyx was evaluated in combination with a 26-week steroid taper and compared to a placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at week 52 compared to placebo, the study's primary endpoint. There was also no statistical improvement in secondary endpoints, but Novartis did state that patients treated with Cosentyx showed numerically better outcomes compared to placebo for cumulative steroid dose and steroid-related toxicity. Safety remained consistent with previous studies and real-world data of Cosentyx patients. The randomised, double-blind, placebo-controlled study enrolled 354 patients from 27 countries. Novartis' chief medical officer Dr Shreeram Aradhye, said: "While the Phase III results of GCAptAIN did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases.' Novartis will complete a full evaluation of the GCAptAIN data, with the findings shared at a future date. Currently, treatment includes corticosteroids, usually prednisone, as a first-line treatment. Patients may also be treated with Actemra (tocilizumab), an IL-6 receptor antagonist. There are a number of candidates in mid-stage and late-stage studies, including BMS' Orencia (abatacept), which is in a Phase III trial in GCA. Novartis' Cosentyx is a fully human biologic that directly inhibits interleukin-17A. It acts by neutralising IL-17A, which reduces inflammation associated with autoimmune and inflammatory conditions. It was first approved by the US Food and Drug Administration (FDA) in January 2015 for the treatment of moderate-to-severe plaque psoriasis in adults. It has since been approved for use in children aged six years and over with plaque psoriasis, adults with hidradenitis suppurativa (HS), and adults with active psoriatic arthritis (PsA), among others. GlobalData analysis suggests Cosentyx will make peak annual sales of $8.2bn in 2028 before sales start to drop. This will be largely related to the US drug expiry for Cosentyx in January 2029, allowing generic versions of the therapy to enter the market. GlobalData is the parent company of Clinical Trials Arena. "Novartis' Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
03-07-2025
- Health
- Bloomberg
Novartis Blockbuster Antibody Drug Fails in Late-Stage Trial
Novartis AG 's drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company's efforts to find new uses for the blockbuster medicine. The therapy, already one of Novartis's top sellers, did not demonstrate statistically significant improvement in adult patients suffering from giant cell arteritis, an ailment that can cause loss of vision and life-threatening aneurysms, according to a statement Thursday. The drug was compared with placebo, with all trial participants also getting a steroid.
